Gyre Therapeutics (GYRE) Income from Continuing Operations (2010 - 2026)
Gyre Therapeutics (GYRE) reported Income from Continuing Operations of 9858000.0 for Q1 2026, down 364.01% year-over-year from 3734000.0 in Q1 2025, and up 53.04% on a QoQ basis from 20993000.0 in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Income from Continuing Operations data on file, last reported at 9858000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 364.01% year-over-year to 9858000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23339000.0 (down 126.28% YoY) and the FY2025 annual result came in at 9747000.0, down 136.98% from the prior year.
- Income from Continuing Operations improved to 9858000.0 in Q1 2026 per GYRE's latest filing, from 20993000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 51632000.0 in Q2 2022 and bottomed at 100977000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 2856000.0 (2024), against an average of 6169647.06.
- The widest annual swing landed in 2022, when Income from Continuing Operations soared 359.42%; it then slumped 364.01% in 2026.
- Tracing GYRE's Income from Continuing Operations over 5 years: stood at 27898000.0 in 2022, then plunged by 261.95% to 100977000.0 in 2023, then jumped by 78.77% to 21442000.0 in 2024, then climbed by 2.09% to 20993000.0 in 2025, then jumped by 53.04% to 9858000.0 in 2026.
- Per Business Quant, the three latest GYRE Income from Continuing Operations figures stand at 9858000.0 (Q1 2026), 20993000.0 (Q4 2025), and 5936000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | -9.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.86 Mn |
| Dec 31, 2025 | -20.99 Mn |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | -21.44 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 4.54 Mn |
| Mar 31, 2024 | 9.94 Mn |
| Dec 31, 2023 | -100.98 Mn |
| Sep 30, 2023 | 7.51 Mn |
| Jun 30, 2023 | 3.77 Mn |
| Mar 31, 2023 | 4.22 Mn |
| Dec 31, 2022 | -27.90 Mn |
| Sep 30, 2022 | -4.88 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | -14.54 Mn |
| Dec 31, 2021 | -20.31 Mn |
| Sep 30, 2021 | -25.22 Mn |
| Jun 30, 2021 | -19.90 Mn |
| Mar 31, 2021 | -22.42 Mn |
| Dec 31, 2020 | -19.55 Mn |
| Sep 30, 2020 | -16.03 Mn |
| Jun 30, 2020 | -17.25 Mn |
| Mar 31, 2020 | -4.73 Mn |
| Dec 31, 2019 | -13.53 Mn |
| Sep 30, 2019 | -12.71 Mn |
| Jun 30, 2019 | -13.78 Mn |
| Mar 31, 2019 | -15.08 Mn |
| Dec 31, 2018 | -13.22 Mn |
| Sep 30, 2018 | -7.69 Mn |
| Jun 30, 2018 | -6.51 Mn |
| Mar 31, 2018 | -5.04 Mn |
| Dec 31, 2017 | -5.96 Mn |
| Sep 30, 2017 | -5.79 Mn |
| Jun 30, 2017 | -5.89 Mn |
| Mar 31, 2017 | -4.14 Mn |
| Dec 31, 2016 | -3.75 Mn |
| Sep 30, 2016 | -4.77 Mn |
| Jun 30, 2016 | -4.83 Mn |
| Mar 31, 2016 | -3.59 Mn |
| Dec 31, 2015 | -6.51 Mn |
| Sep 30, 2015 | -3.61 Mn |
| Jun 30, 2015 | -4.34 Mn |
| Mar 31, 2015 | -6.75 Mn |
| Dec 31, 2014 | -4.56 Mn |
| Sep 30, 2014 | -4.86 Mn |
| Jun 30, 2014 | -8.14 Mn |
| Mar 31, 2014 | -15.00 Mn |
| Dec 31, 2013 | -13.36 Mn |
| Sep 30, 2013 | -12.90 Mn |
| Jun 30, 2013 | -12.37 Mn |
| Mar 31, 2013 | -8.07 Mn |
| Dec 31, 2012 | -16.03 Mn |
| Sep 30, 2012 | -7.88 Mn |
| Jun 30, 2012 | 14.49 Mn |
| Mar 31, 2012 | 2.26 Mn |
| Dec 31, 2011 | -9.81 Mn |
| Sep 30, 2011 | -9.05 Mn |
| Jun 30, 2011 | -2.26 Mn |
| Mar 31, 2011 | 12.59 Mn |
| Dec 31, 2010 | -2.16 Mn |
| Sep 30, 2010 | 2.49 Mn |
| Jun 30, 2010 | 3.78 Mn |